Home Featured Page 144

Featured

Latest

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Small Pharma Enters Into Automatic Share Purchase Plan

Numinus provides update on acquisition integration and announces new client financing...

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

PT355 – Ifetayo Harvey – The Drug War, Caregiving, and Blue...

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke...

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual...

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Pain and Psychedelics – Reviewing a Newly Published Paper

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment...

New Psychedelic Entactogens: Designer Drugs Produce Designer Effects

1...143144145...301 Page 144 of 301

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Small Pharma Enters Into Automatic Share Purchase Plan

Numinus provides update on acquisition integration and announces new client financing...

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

PT355 – Ifetayo Harvey – The Drug War, Caregiving, and Blue...

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke...

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual...

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Pain and Psychedelics – Reviewing a Newly Published Paper

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment...

New Psychedelic Entactogens: Designer Drugs Produce Designer Effects

EDITOR PICKS

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY